Urovant draws down $15M in loan facility

Urology-focused biotech Urovant drew down $15 million under a newly announced loan facility with Hercules Capital. Urovant Sciences Ltd. (NASDAQ:UROV) can draw down the remaining $85 million in three tranches through June 2021...